Groupe de Recherche et d’Action pour la Santé
Accueil > Solidarité Nord/Sud > R&D sur les maladies négligées : résultats d’une nouvelle analyse de MSF et (...)

R&D sur les maladies négligées : résultats d’une nouvelle analyse de MSF et DNDi

samedi 15 décembre 2012

"Over the past decade, neglected diseases have attracted increased attention and larger investments in research. Even often overlooked tropical diseases such as sleeping sickness and leishmaniasis have received more funding. “These Cinderella diseases, long ignored and underappreciated, are a rags-to-riches story,” said Margaret Chan, director-general of the World Health Organization, in an address in May. But these newfound ‘riches’ have given rise to just a few dozen newly approved therapies and only a handful of truly novel drugs. A new analysis by Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases Initiative (DNDi) finds that the rate of approvals for new compounds over the past decade is roughly the same as it was during the previous two-and-a-half decades, when the diseases received little attention..."

Voir en ligne : Neglected diseases see few new drugs despite upped investment

SPIP | squelette | | Plan du site | Suivre la vie du site RSS 2.0 | © GRAS asbl 2012